FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Evi Kostenis

Research Profile

Chemicals & Drugs

Physiology

Anatomy

Concepts & Ideas

Living Beings

Procedures

Radioligand Assay

Co-author Network

Publications

TOP 3
R Schrage; Wk Seemann; Kurt Racké; Clelia Dallanoce; Marco De Amici; Ulrike Holzgrabe; J Klöckner; Evi Kostenis; Klaus Mohr
Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor.
Elisabeth Christiansen; Maria E Due-Hansen; Manuel Grundmann; Ellen Hagesaether; Steffen V F Hansen; Brian D Hudson; Matthias U Kassack; Evi Kostenis; Stine B Markussen; Graeme Milligan; Johannes Schmidt; Christian Urban; Mohamed Zaibi; Michael A Cawthorne; Trond Ulven
Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
Magalie Rocheville; Julio Martin; Jeff Jerman; Evi Kostenis
Mining the potential of label-free biosensors for seven-transmembrane receptor drug discovery.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Evi Kostenis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: R Schrage; Wk Seemann; Kurt Racké; Clelia Dallanoce; Marco De Amici; Ulrike Holzgrabe; J Klöckner; Evi Kostenis; Klaus Mohr
Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor.
British journal of pharmacology 2013;169(2):357-70.
2013: Elisabeth Christiansen; Maria E Due-Hansen; Manuel Grundmann; Ellen Hagesaether; Steffen V F Hansen; Brian D Hudson; Matthias U Kassack; Evi Kostenis; Stine B Markussen; Graeme Milligan; Johannes Schmidt; Christian Urban; Mohamed Zaibi; Michael A Cawthorne; Trond Ulven
Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
Journal of medicinal chemistry 2013;56(3):982-92.
2013: Magalie Rocheville; Julio Martin; Jeff Jerman; Evi Kostenis
Mining the potential of label-free biosensors for seven-transmembrane receptor drug discovery.
Progress in molecular biology and translational science 2013;115():123-42.
2013: A S Ahmedat; Uwe R Juergens; W K Seemann; Evi Kostenis; Klaus Mohr; M Warnken; Kurt Racké
Pro-fibrotic processes in human lung fibroblasts are driven by an autocrine/paracrine endothelinergic system.
British journal of pharmacology 2013;168(2):471-87.
2012: Brian D Hudson; Evi Kostenis; David R Adams; Elisabeth Christiansen; Manuel Grundmann; Irina G Tikhonova; Trond Ulven; Graeme Milligan
Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2012;26(12):4951-65.
2012: Elisabeth Christiansen; Maria E Due-Hansen; Manuel Grundmann; Brian D Hudson; Matthias U Kassack; Evi Kostenis; Graeme Milligan; Ralf Schröder; Michael A Cawthorne; Christian Urban; Trond Ulven
Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
Journal of medicinal chemistry 2012;55(14):6624-8.
2012: Stefanie Blättermann; Andreas Bock; Jürgen Gäb; Angel Gonzalez; Michael Gütschow; Akos Heinemann; Stephanie Hennen; Viktoria Konya; Petra Luschnig; Klaus Mohr; Philipp Aaron Ottersbach; Leonardo Pardo; Lucas Peters; Ralf Schröder; Rahul Tyagi; Trond Ulven; C David Weaver; Evi Kostenis
A biased ligand for OXE-R uncouples Gα and Gβγ signaling within a heterotrimer.
Nature chemical biology 2012;8(7):631-8.
2012: Miriam Sedej; Anela Vukoja; Kathrin Bell; Akos Heinemann; Evi Kostenis; Wolfgang Platzer; Ralf Schröder; Maria Waldhoer
D-type prostanoid receptor enhances the signaling of chemoattractant receptor-homologous molecule expressed on T(H)2 cells.
The Journal of allergy and clinical immunology 2012;129(2):492-500, 500.e1-9.
2012: Andreas Bock; Clelia Dallanoce; Marco De Amici; Carsten Hoffmann; Ulrike Holzgrabe; Anna Kebig; Jessica Klöckner; Evi Kostenis; Carlo Matera; Nicole Merten; Anke Müller; Lucas Peters; Jens Schmitz; Ramona Schrage; Jasmin Schrobang-Ley; Katharina Simon; Christian Tränkle; Julia Bätz; Klaus Mohr
The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling.
Nature communications 2012;3():1044.
2012: Ralf Schröder; Trond Ulven; Jennifer L Whistler; Luzheng Xue; Akos Heinemann; Nora Kampitsch; Viktoria Konya; Lene Martini; Roy Pettipher; Evi Kostenis
PGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2.
PloS one 2012;7(3):e33329.
2011: Klaus Mohr; Evi Kostenis
Signaling pathways: Purinosomes under GPCR control.
Nature chemical biology 2011;7(12):860-1.
2011: Ralf Schröder; Wiebke Seemann; Stefanie Blättermann; Christel Drewke; Jesus Gomeza; Manuel Grundmann; Nicole Janssen; Dorina Kaufel; Nicole Merten; Graeme Milligan; Klaus Mohr; Lucas Peters; Johannes Schmidt; Evi Kostenis
Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells.
Nature protocols 2011;6(11):1748-60.
2011: Elisabeth Christiansen; Maria E Due-Hansen; Manuel Grundmann; Ellen Hagesaether; Matthias U Kassack; Evi Kostenis; Leonardo Pardo; Johannes Schmidt; Susanne Ullrich; Christian Urban; Trond Ulven
Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
Journal of medicinal chemistry 2011;54(19):6691-703.
2011: Nariman A B Balenga; Stefanie Blättermann; Andrew J Brown; Akos Heinemann; Julia Kargl; Evi Kostenis; Wolfgang Platzer; Ralf Schröder; Elma Aflaki; Maria Waldhoer
GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils.
Cell research 2011;21(10):1452-69.
2011: F Lamyel; H Meurs; A Miller-Larsson; K Mohr; A S Ahmedat; R Gosens; Evi Kostenis; W K Seemann; M Smit; M Warnken-Uhlich; Kurt Racké
The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts.
Naunyn-Schmiedeberg's archives of pharmacology 2011;384(2):133-45.
2011: Nicola J Smith; Leigh A Stoddart; Irina G Tikhonova; Christian Tränkle; Trond Ulven; Richard J Ward; David R Adams; Brian D Hudson; Evi Kostenis; Joanne C Morris; Graeme Milligan
Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator.
Molecular pharmacology 2011;80(1):163-73.
2011: Johannes Schmidt; Kathrin Liebscher; Nicole Merten; Manuel Grundmann; Manfred Mielenz; Helga Sauerwein; Elisabeth Christiansen; Maria E Due-Hansen; Trond Ulven; Susanne Ullrich; Jesús Gomeza; Christel Drewke; Evi Kostenis
Conjugated linoleic acids mediate insulin release through islet G protein-coupled receptor FFA1/GPR40.
The Journal of biological chemistry 2011;286(14):11890-4.
2011: Johannes Schmidt; Nicola J Smith; Elisabeth Christiansen; Irina G Tikhonova; Manuel Grundmann; Brian D Hudson; Richard J Ward; Christel Drewke; Graeme Milligan; Evi Kostenis; Trond Ulven
Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3.
The Journal of biological chemistry 2011;286(12):10628-40.
2010: Trond Ulven; Evi Kostenis
Novel CRTH2 antagonists: a review of patents from 2006 to 2009.
Expert opinion on therapeutic patents 2010;20(11):1505-30.
2010: Ralf Schröder; Nicole Janssen; Johannes Schmidt; Anna Kebig; Nicole Merten; Stephanie Hennen; Anke Müller; Stefanie Blättermann; Marion Mohr-Andrä; Sabine Zahn; Jörg Wenzel; Nicola J Smith; Jesús Gomeza; Christel Drewke; Graeme Milligan; Klaus Mohr; Evi Kostenis
Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements.
Nature biotechnology 2010;28(9):943-9.
2010: Christopher M Henstridge; Nariman Ab Balenga; Ralf Schröder; Julia K Kargl; Wolfgang Platzer; Lene Martini; Simon Arthur; June Penman; Jennifer L Whistler; Evi Kostenis; Maria Waldhoer; Andrew J Irving
GPR55 ligands promote receptor coupling to multiple signalling pathways.
British journal of pharmacology 2010;160(3):604-14.
2010: Klaus Mohr; Christian Tränkle; Evi Kostenis; Elisabetta Barocelli; Marco De Amici; Ulrike Holzgrabe
Rational design of dualsteric GPCR ligands: quests and promise.
British journal of pharmacology 2010;159(5):997-1008.
2010: Øystein Rist; Marie Grimstrup; Jean-Marie Receveur; Thomas M Frimurer; Trond Ulven; Evi Kostenis; Thomas Högberg
Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 1.
Bioorganic & medicinal chemistry letters 2010;20(3):1177-80.
2010: Marie Grimstrup; Øystein Rist; Jean-Marie Receveur; Thomas M Frimurer; Trond Ulven; Jesper M Mathiesen; Evi Kostenis; Thomas Högberg
Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 2.
Bioorganic & medicinal chemistry letters 2010;20(3):1181-5.
2009: Valeria Camarda; Carmela Fischetti; Nicholas Anzellotti; Paola Molinari; Caterina Ambrosio; Evi Kostenis; Domenico Regoli; Claudio Trapella; Remo Guerrini; Salvadori Severo; Girolamo Calo
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5.
Naunyn-Schmiedeberg's archives of pharmacology 2009;379(6):599-607.
2009: Petra Hillmann; Geun-Yung Ko; Andreas Spinrath; Alexandra Raulf; Ivar von Kügelgen; Samuel C Wolff; Robert A Nicholas; Evi Kostenis; Hans-Dieter Höltje; Christa E Müller
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
Journal of medicinal chemistry 2009;52(9):2762-75.
2009: Johannes Antony; Kerstin Kellershohn; Marion Mohr-Andrä; Anna Kebig; Stefanie Prilla; Mathias Muth; Eberhard Heller; Teresa Disingrini; Clelia Dallanoce; Simona Bertoni; Jasmin Schrobang; Christian Tränkle; Evi Kostenis; Arthur Christopoulos; Hans-Dieter Höltje; Elisabetta Barocelli; Marco De Amici; Ulrike Holzgrabe; Klaus Mohr
Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2009;23(2):442-50.
2009: Jakob L Hansen; Jonas T Hansen; Tobias Speerschneider; Christina Lyngsø; Niels Erikstrup; Ethan S Burstein; David M Weiner; Thomas Walther; Noriko Makita; Taroh Iiri; Nicole Merten; Evi Kostenis; Søren P Sheikh
Lack of evidence for AT1R/B2R heterodimerization in COS-7, HEK293, and NIH3T3 cells: how common is the AT1R/B2R heterodimer?
The Journal of biological chemistry 2009;284(3):1831-9.
2009: Ralf Schröder; Nicole Merten; Jesper Mosolff Mathiesen; Lene Martini; Anamarija Kruljac-Letunic; Friederike Krop; Andree Blaukat; Ye Fang; Elizabeth Tran; Trond Ulven; Christel Drewke; Jennifer Whistler; Leonardo Pardo; Jesús Gomeza; Evi Kostenis
The C-terminal tail of CRTH2 is a key molecular determinant that constrains Galphai and downstream signaling cascade activation.
The Journal of biological chemistry 2009;284(2):1324-36.
2009: Anna Kebig; Evi Kostenis; Klaus Mohr; Marion Mohr-Andrä
An optical dynamic mass redistribution assay reveals biased signaling of dualsteric GPCR activators.
Journal of receptor and signal transduction research 2009;29(3-4):140-5.
2008: Elisabeth Christiansen; Christian Urban; Nicole Merten; Kathrin Liebscher; Kasper K Karlsen; Alexandra Hamacher; Andreas Spinrath; Andrew D Bond; Christel Drewke; Susanne Ullrich; Matthias U Kassack; Evi Kostenis; Trond Ulven
Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes.
Journal of medicinal chemistry 2008;51(22):7061-4.
2008: Hyun-Ji Kim; Hyung-Mun Yun; Taehyun Kim; Ghilsoo Nam; Eun Joo Roh; Evi Kostenis; Hea-Young Park Choo; Ae Nim Pae; Hyewhon Rhim
Functional human 5-HT6 receptor assay for high throughput screening of chemical ligands and binding proteins.
Combinatorial chemistry & high throughput screening 2008;11(4):316-24.
2007: Julia F Royer; Petra Schratl; S Lorenz; Evi Kostenis; Trond Ulven; Rufina Schuligoi; Bernhard A Peskar; Akos Heinemann
A novel antagonist of CRTH2 blocks eosinophil release from bone marrow, chemotaxis and respiratory burst.
Allergy 2007;62(12):1401-9.
2007: Trond Ulven; Michael J Gallen; Mads C Nielsen; Nicole Merten; Carola Schmidt; Klaus Mohr; Christian Tränkle; Evi Kostenis
Synthesis and in vitro evaluation of a selective antagonist and the corresponding radioligand for the prostaglandin D2 receptor CRTH2.
Bioorganic & medicinal chemistry letters 2007;17(21):5924-7.
2007: Petra Schratl; Julia F Royer; Evi Kostenis; Trond Ulven; Eva M Sturm; Maria Waldhoer; Gerald Hoefler; Rufina Schuligoi; Irmgard Th Lippe; Bernhard A Peskar; Akos Heinemann
The role of the prostaglandin D2 receptor, DP, in eosinophil trafficking.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(7):4792-9.
2007: Hyung-Mun Yun; Sunoh Kim; Hyun-Ji Kim; Evi Kostenis; Jae Il Kim; Jae Young Seong; Ja-Hyun Baik; Hyewhon Rhim
The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn.
The Journal of biological chemistry 2007;282(8):5496-505.
2007: Lena Uller; Jesper Mosolff Mathiesen; Lisa Alenmyr; Magnus Korsgren; Trond Ulven; Thomas Högberg; Gunnar Andersson; Carl G A Persson; Evi Kostenis
Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation.
Respiratory research 2007;8():16.
2006: Trond Ulven; Jean-Marie Receveur; Marie Grimstrup; Øystein Rist; Thomas M Frimurer; Lars-Ole Gerlach; Jesper Mosolff Mathiesen; Evi Kostenis; Lena Uller; Thomas Högberg
Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits.
Journal of medicinal chemistry 2006;49(23):6638-41.
2006: Ulf Sürig; Klaudia Gaal; Evi Kostenis; Christian Tränkle; Klaus Mohr; Ulrike Holzgrabe
Muscarinic allosteric modulators: atypical structure-activity-relationships in bispyridinium-type compounds.
Archiv der Pharmazie 2006;339(4):207-12.
2006: Evi Kostenis; Trond Ulven
Emerging roles of DP and CRTH2 in allergic inflammation.
Trends in molecular medicine 2006;12(4):148-58.
2006: Jesper Mosolff Mathiesen; Arthur Christopoulos; Trond Ulven; Julia F Royer; Mercedes Campillo; Akos Heinemann; Leonardo Pardo; Evi Kostenis
On the mechanism of interaction of potent surmountable and insurmountable antagonists with the prostaglandin D2 receptor CRTH2.
Molecular pharmacology 2006;69(4):1441-53.
2006: Trond Ulven; Evi Kostenis
Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation.
Current topics in medicinal chemistry 2006;6(13):1427-44.
2006: Evi Kostenis
G proteins in drug screening: from analysis of receptor-G protein specificity to manipulation of GPCR-mediated signalling pathways.
Current pharmaceutical design 2006;12(14):1703-15.
2006: Graeme Milligan; Evi Kostenis
Heterotrimeric G-proteins: a short history.
British journal of pharmacology 2006;147 Suppl 1():S46-55.
2005: Evi Kostenis; Magali Waelbroeck; Graeme Milligan
Techniques: promiscuous Galpha proteins in basic research and drug discovery.
Trends in pharmacological sciences 2005;26(11):595-602.
2005: Thomas M Frimurer; Trond Ulven; Christian E Elling; Lars-Ole Gerlach; Evi Kostenis; Thomas Högberg
A physicogenetic method to assign ligand-binding relationships between 7TM receptors.
Bioorganic & medicinal chemistry letters 2005;15(16):3707-12.
2005: Jesper Mosolff Mathiesen; Trond Ulven; Lene Martini; Lars-Ole Gerlach; Akos Heinemann; Evi Kostenis
Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2.
Molecular pharmacology 2005;68(2):393-402.
2005: Maria Waldhoer; Jamie Fong; Robert M Jones; Mary M Lunzer; Shiv K Sharma; Evi Kostenis; Philip S Portoghese; Jennifer L Whistler
A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(25):9050-5.
2005: Evi Kostenis; Graeme Milligan; Arthur Christopoulos; Carlos F Sanchez-Ferrer; Silvia Heringer-Walther; Patrick M Sexton; Florian Gembardt; Elaine Kellett; Lene Martini; Patrick Vanderheyden; Heinz-Peter Schultheiss; Thomas Walther
G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor.
Circulation 2005;111(14):1806-13.
2005: Evi Kostenis; Lene Martini; James Ellis; Maria Waldhoer; Arne Heydorn; Mette M Rosenkilde; Pia K Norregaard; Rasmus Jorgensen; Jennifer L Whistler; Graeme Milligan
A highly conserved glycine within linker I and the extreme C terminus of G protein alpha subunits interact cooperatively in switching G protein-coupled receptor-to-effector specificity.
The Journal of pharmacology and experimental therapeutics 2005;313(1):78-87.
2005: Trond Ulven; Evi Kostenis
Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist.
Journal of medicinal chemistry 2005;48(4):897-900.
2004: Arne Heydorn; Richard J Ward; Rasmus Jorgensen; Mette M Rosenkilde; Thomas M Frimurer; Graeme Milligan; Evi Kostenis
Identification of a novel site within G protein alpha subunits important for specificity of receptor-G protein interaction.
Molecular pharmacology 2004;66(2):250-9.
2004: Evi Kostenis
Novel clusters of receptors for sphingosine-1-phosphate, sphingosylphosphorylcholine, and (lyso)-phosphatidic acid: new receptors for "old" ligands.
Journal of cellular biochemistry 2004;92(5):923-36.
2004: Evi Kostenis
A glance at G-protein-coupled receptors for lipid mediators: a growing receptor family with remarkably diverse ligands.
Pharmacology & therapeutics 2004;102(3):243-57.
2004: Yi-Zhun Zhu; Zhong Jing Wang; Yi Chun Zhu; Li Zhang; Reida M E Oakley; Chin Wee Chung; Kiat Wee Lim; How-Sung Lee; Marie L Ozoux; Wolfgang Linz; Michael Böhm; Evi Kostenis
Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile.
American journal of physiology. Heart and circulatory physiology 2004;286(3):H830-6.
2003: Anke Niedernberg; Sorin Tunaru; Andree Blaukat; Bruce Harris; Evi Kostenis
Comparative analysis of functional assays for characterization of agonist ligands at G protein-coupled receptors.
Journal of biomolecular screening 2003;8(5):500-10.
2003: Alexandre Brkovic; Almut Hattenberger; Evi Kostenis; Thomas Klabunde; Stefanie Flohr; Michael Kurz; Steve Bourgault; Alain Fournier
Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay.
The Journal of pharmacology and experimental therapeutics 2003;306(3):1200-9.
2003: Anke Niedernberg; Sorin Tunaru; Andree Blaukat; Ali Ardati; Evi Kostenis
Sphingosine 1-phosphate and dioleoylphosphatidic acid are low affinity agonists for the orphan receptor GPR63.
Cellular signalling 2003;15(4):435-46.
2003: Anke Niedernberg; Andree Blaukat; Torsten Schöneberg; Evi Kostenis
Regulated and constitutive activation of specific signalling pathways by the human S1P5 receptor.
British journal of pharmacology 2003;138(3):481-93.
2003: Kirsten Uhlenbrock; Jochen Huber; Ali Ardati; Andreas E Busch; Evi Kostenis
Fluid shear stress differentially regulates gpr3, gpr6, and gpr12 expression in human umbilical vein endothelial cells.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2003;13(2):75-84.
2003: Bodo Cremers; Markus Flesch; Evi Kostenis; Christoph Maack; Anke Niedernberg; Alexander Stoff; Michael Südkamp; Olaf Wendler; Michael Böhm
Modulation of myocardial contractility by lysophosphatidic acid (LPA).
Journal of molecular and cellular cardiology 2003;35(1):71-80.
2002: Kirsten Uhlenbrock; Hans Gassenhuber; Evi Kostenis
Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors.
Cellular signalling 2002;14(11):941-53.
2002: Anke Niedernberg; Constanze R Scherer; Andreas E Busch; Evi Kostenis
Comparative analysis of human and rat S1P(5) (edg8): differential expression profiles and sensitivities to antagonists.
Biochemical pharmacology 2002;64(8):1243-50.
2002: Valeria Camarda; Remo Guerrini; Evi Kostenis; Anna Rizzi; Girolamo Calò; Almut Hattenberger; Marina Zucchini; Severo Salvadori; Domenico Regoli
A new ligand for the urotensin II receptor.
British journal of pharmacology 2002;137(3):311-4.
2002: Stefanie Flohr; Michael Kurz; Evi Kostenis; Alexandre Brkovich; Alain Fournier; Thomas Klabunde
Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.
Journal of medicinal chemistry 2002;45(9):1799-805.
2002: Evi Kostenis
Potentiation of GPCR-signaling via membrane targeting of G protein alpha subunits.
Journal of receptor and signal transduction research 2002;22(1-4):267-81.
2002: Valeria Camarda; Anna Rizzi; Girolamo Calò; Gabrielle Gendron; Stephan I Perron; Evi Kostenis; Clive Beggs; Francesco Mascoli; Domenico Regoli
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.
Naunyn-Schmiedeberg's archives of pharmacology 2002;365(2):141-9.
2001: Evi Kostenis
Is Galpha16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors?
Trends in pharmacological sciences 2001;22(11):560-4.
2001: Christian Tränkle; Evi Kostenis; Klaus Mohr
Muscarinic allosteric modulation: M2/M3 subtype selectivity of gallamine is independent of G-protein coupling specificity.
Naunyn-Schmiedeberg's archives of pharmacology 2001;364(2):172-8.
2000: H M Botero Cid; Christian Tränkle; Knut Baumann; R Pick; E Mies-Klomfass; Evi Kostenis; Klaus Mohr; Ulrike Holzgrabe
Structure-activity relationships in a series of bisquaternary bisphthalimidine derivatives modulating the muscarinic M(2)-receptor allosterically.
Journal of medicinal chemistry 2000;43(11):2155-64.
1999: T Nassif-Makki; Christian Tränkle; Darius P Zlotos; G Bejeuhr; A Cambareri; C Pfletschinger; Evi Kostenis; Klaus Mohr; Ulrike Holzgrabe
Bisquaternary ligands of the common allosteric site of M2 acetylcholine receptors: search for the minimum essential distances between the pharmacophoric elements.
Journal of medicinal chemistry 1999;42(5):849-58.